Valuation: Ionis Pharmaceuticals, Inc.

Market Cap 9.93B 8.5B 7.96B 7.28B 13.67B 950B 13.85B 94.01B 36.66B 477B 37.28B 36.47B 1,578B P/E 2026 *
-16.4x
P/E 2027 * -31.6x
Enterprise Value 9.82B 8.42B 7.87B 7.21B 13.53B 940B 13.71B 93.04B 36.28B 472B 36.89B 36.09B 1,562B EV / Sales 2026 *
10.8x
EV / Sales 2027 * 7.12x
Free-Float
99.05%
Yield 2026 *
-
Yield 2027 * -
1 day+2.33%
1 week+4.21%
Current month+18.02%
1 month+8.05%
3 months-19.68%
6 months-28.50%
Current year-22.77%
1 week 58.02
Extreme 58.0237
61.36
1 month 51.28
Extreme 51.28
61.36
Current year 50
Extreme 50.005
86.74
1 year 41.7
Extreme 41.705
86.74
3 years 23.95
Extreme 23.95
86.74
5 years 23.95
Extreme 23.95
86.74
10 years 23.95
Extreme 23.95
86.74
Manager TitleAgeSince
Investor Relations Contact 60 01/07/2012
Chief Executive Officer 64 01/01/2020
Director of Finance/CFO 64 01/05/2000
Director TitleAgeSince
Director/Board Member 64 13/12/2005
Director/Board Member 73 01/05/2002
Director/Board Member 64 25/03/2019
Date Insider Type Main position Quantity % Market Cap.
31/07/26 Buy

Director

5,000 0.0030%
15/07/26 Free

Director

3,399 0.0021%
15/07/26 Free

Director

3,399 0.0021%
Change 5-day change 1-year change 3-year change Capi.($)
+2.31%+4.21%+46.10%+53.48% 9.93B
-1.22%+3.28%+2.13%+22.51% 51.61B
-0.11%-1.69%+484.27%+554.97% 44.89B
-0.13%+7.75%+38.25%+20.62% 42.77B
-1.27%+2.14%+19.98%+86.19% 42.58B
+0.88%-3.48%+17.20%+57.20% 31.82B
-0.53%+3.61%+32.54%+144.72% 17.33B
-1.01%+1.34% - - 16.63B
+0.58%+4.66%+9.77%+30.87% 14.76B
-0.31%+2.88%+79.70%+48.47% 14.09B
Average -0.07%+4.78%+81.10%+113.22% 28.64B
Weighted average by Cap. -0.33%+5.10%+100.73%+135.76%

Financials

2026 *2027 *
Net sales 913M 782M 732M 670M 1.26B 87.39B 1.27B 8.65B 3.37B 43.9B 3.43B 3.36B 145B 1.4B 1.2B 1.12B 1.03B 1.93B 134B 1.96B 13.28B 5.18B 67.39B 5.26B 5.15B 223B
Net income -602M -516M -483M -442M -829M -57.64B -840M -5.7B -2.22B -28.96B -2.26B -2.21B -95.77B -326M -279M -261M -239M -449M -31.18B -455M -3.09B -1.2B -15.66B -1.22B -1.2B -51.8B
Net Debt -103M -88.2M -82.53M -75.54M -142M -9.85B -144M -975M -380M -4.95B -387M -378M -16.37B 57.45M 49.22M 46.05M 42.15M 79.11M 5.5B 80.15M 544M 212M 2.76B 216M 211M 9.13B
Logo Ionis Pharmaceuticals, Inc.
Ionis Pharmaceuticals, Inc. develops six marketed medicines for serious diseases, including medicines for neurologic and cardiovascular diseases. Its marketed medicines consist of TRYNGOLZA, WAINUA (eplontersen), SPINRAZA (nusinersen), QALSODY (tofersen), TEGSEDI (inotersen) and WAYLIVRA (volanesorsen). TRYNGOLZA reduces triglyceride levels in adults with familial chylomicronemia syndrome (FCS). WAINUA is approved for the treatment of the polyneuropathy of hereditary transthyretin-medicated amyloidosis (ATTRv-PN) in adults. SPINRAZA is used for the treatment of pediatric and adult patients with spinal muscular atrophy. QALSODY is approved for the treatment of Amyotrophic Lateral Sclerosis in adults who have a mutation in the superoxide dismutase 1 (SOD1) gene, or SOD1-ALS. TEGSEDI is approved for the treatment of ATTRv-PN in adults. WAYLIVRA is approved as an adjunct to diet in adult patients with genetically confirmed FCS and at high risk of acute, potentially fatal pancreatitis.
Employees
1,480
Date Price Change Volume
24/08/26 $61.01 +2.12% 563,455
21/08/26 $59.74 +1.67% 2,723,906
20/08/26 $58.76 -3.36% 2,124,846
19/08/26 $60.80 +1.98% 3,137,560
18/08/26 $59.62 +1.69% 3,192,640
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
A
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
24
Last Close Price
59.74USD
Average target price
88.00USD
Spread / Average Target
+47.30%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. IONS Stock